BERGO 0.5mg Price in UAE

Overview

Welcome to Dwaey, specifically on BERGO 0.5mg page.
This medicine contains an important and useful components, as it consists of
Cabergolineis available in the market in concentration

Name

Cabergoline

Precaution

CV disease, Raynaud's syndrome, renal or hepatic impairment, peptic ulcer, GI bleeding, history of psychosis, hypertension. May affect ability to drive or operate machinery. Pregnancy, lactation. Prolonged use and/or usage of high doses may lead to psychiatric disorders, pleural/retroperitoneal fibrosis or cardiac valvular fibrosis. Monitor serum prolactin level mthly until normalisation. Monitor hepatic function regularly in patients with hepatic impairment. Lactation: excretion in milk unknown; use with caution

Indication

Hyperprolactinemia, prolactinomas, parkinson's disease, uterine fibroids, acromegaly, cushing's disease, pituitary adenomas, lactation suppression

Contra indication

Hypersensitivity to ergot derivatives. Uncontrolled hypertension.

Side Effect

>10% Nausea (27%),Headache (26%),Dizziness (15%),Constipation (10%) 1-10% Asthenia (9%),Fatigue (7%),Abdominal pain (5%),Somnolence (5%),Postural hypotension (4%),Depression (3%),Dyspepsia (2%),Nervousness (2%),Abnormal vision (1%),Breast pain (1%),Dysmenorrhea (1%),Hot flashes (1%),Paresthesia (1%) Potentially Fatal: Risk of serotinin syndrome with sibutramine; avoid combination.

Pregnancy Category ID

Mode of Action

Cabergoline is a long-acting dopamine D2-agonist. It inhibits prolactin secretion through hypothalamic inhibitory control exerted through the release of dopamine.

Interaction

Increased risk of orthostatic hypotension when used with antihypertensives. May increase vasoconstriction effect of dopamine. May reduce vasodilation effect of nitroglycerin. Concurrent use with SSRIs or TCAs may increase the risk of serotonin syndrome. Potentially Fatal: Risk of serotonin syndrome with sibutramine.